Why Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update
Tucked in its Q2 earnings release, Qualigen Therapeutics Inc (NASDAQ:QLGN) announced deprioritizing the QN-165 COVID-19 program, sending shares to fall to…
Qualigen Therapeutics Q2 EPS $(0.18) Up From $(0.41) YoY, Sales $1.10M Up From $837.71K YoY
Qualigen Therapeutics (NASDAQ:QLGN) reported quarterly losses of $(0.18) per share. This is a 56.1 percent increase over losses of $(0.41) per share from the same period last year. The company reported $1.10 million in
25 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Cardiol Therapeutics Inc. (NASDAQ: CRDL) shares rose 25.8% to $3.27 in pre-market trading after dropping around 7% on Monday.
Qualigen Shares Move Higher On Volume Following Circulation Of A European Patent Office Filing For Co.’s ‘SYSTEMS AND METHODS FOR SAMPLE VERIFICATION’
https://register.epo.org/application?number=EP15903259&lng=en&tab=main
Qualigen Therapeutics Q4 EPS $(0.13), Sales $1.90M
Qualigen Therapeutics (NASDAQ:QLGN) reported quarterly losses of $(0.13) per share. The company reported $1.90 million in sales this quarter.